Temat: "Antineoplastic Combined Chemotherapy Protocols" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.
Autorzy:: Lee KH; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea.
Yang IJ; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea.
Ha GW; Biomedical Research Institute, Jeonbuk National University Hospital, Jeonju, Korea.
Lee J; Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
Park YY; Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Lee SH; Department of Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea.
Lee JM; Department of Surgery, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
Bae JH; Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park EJ; Division of Colorectal Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim H; Department of Surgery, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim KY; Department of General Surgery, Wonkwang University Hospital & School of Medicine, Iksan, Korea.
An S; Department of Surgery, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Kim IY; Department of Surgery, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Kim JY; Department of Colorectal Surgery, Chungnam National University Hospital & College of Medicine, Daejeon, Korea. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Mar 29; Vol. 24 (1), pp. 397. Date of Electronic Publication: 2024 Mar 29.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Colonic Neoplasms*/pathology
Adult ; Aged ; Humans ; Middle Aged ; Young Adult ; Chemotherapy, Adjuvant ; Clinical Trials, Phase II as Topic ; Disease-Free Survival ; Multicenter Studies as Topic ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Fluorouracil/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
Autorzy:: Kappel C; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Elliott MJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Kumar V; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Nadler MB; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Desnoyers A; Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada.
Amir E; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. .; Princess Margaret Cancer Centre, 610 University Ave, 700U, 7-721, Toronto, ON, M5G 2M9, Canada. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 07; Vol. 14 (1), pp. 3129. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Breast Neoplasms*/drug therapy
Female ; Humans ; Aminopyridines ; Benzimidazoles ; Cyclin-Dependent Kinase 4 ; Cyclin-Dependent Kinase 6 ; Cyclin-Dependent Kinase Inhibitor Proteins ; Neutropenia/chemically induced ; Purines ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Guiding model-driven combination dose selection using multi-objective synergy optimization.
Autorzy:: Gevertz JL; Department of Mathematics and Statistics, The College of New Jersey, Ewing, New Jersey, USA.
Kareva I; Quantitative Pharmacology Department, EMD Serono, Merck KGaA, Billerica, Massachusetts, USA.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Nov; Vol. 12 (11), pp. 1698-1713. Date of Electronic Publication: 2023 Jul 06.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/pharmacology
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Algorithms*
Humans ; Drug Synergism ; Combined Modality Therapy ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study.
Autorzy:: Guo Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Guo D; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Kong D; Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Bian S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Institute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Lin L; Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical College, Yantai, People's Republic of China.
Fan S; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Q; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Zhao Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Jiang Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Yan J; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Wang Z; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Sun L; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.
Li Y; Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China.; Pokaż więcej
Źródło:: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2219930.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Azacitidine*/adverse effects
Histone Deacetylase Inhibitors*/adverse effects
Leukemia, Myeloid, Acute*/metabolism
Antimetabolites, Antineoplastic*/adverse effects
Adult ; Humans ; Cytarabine/therapeutic use ; Decitabine/adverse effects ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor.
Autorzy:: Weng P; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Yang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Xu S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Zhang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Wu Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Chen Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.; Pokaż więcej
Źródło:: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2220521.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*
Humans ; Prognosis ; Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects ; Leukocytes ; Granulocyte Colony-Stimulating Factor/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP.
Autorzy:: Ma'koseh M; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Farfoura H; Department of Radiology, King Hussein Cancer Center, Amman, Jordan.
Abufara A; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Elmusa R; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Hushki A; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Faqeer N; Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
Ghatasheh H; Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Shahin O; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Alawabdeh T; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Al-Rwashdeh M; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Halahleh K; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Al-Ibraheem A; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Alrabi K; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.; Pokaż więcej
Źródło:: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2198898.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Lymphoma, Large B-Cell, Diffuse*
Humans ; Disease-Free Survival ; Prednisone ; Rituximab/therapeutic use ; Cyclophosphamide ; Vincristine ; Doxorubicin ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Autorzy:: Sutter T; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.
Schittenhelm M; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.
Volken T; ZHAW School of Health Sciences, Institute of Public Health, Winterthur, Switzerland.
Lehmann T; Department of Oncology and Hematology, Cantonal Hospital St Gallen, Zürich, Switzerland.; Pokaż więcej
Źródło:: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2206694. Date of Electronic Publication: 2023 May 11.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/diagnosis
Humans ; Middle Aged ; Retrospective Studies ; Proto-Oncogene Proteins c-bcl-2/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Autorzy:: DerSarkissian M; Analysis Group, Boston, MA, USA.
Cranmer H; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Dabora J; Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.
Bocharova I; Analysis Group, Boston, MA, USA.
Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Cheng M; Analysis Group, Boston, MA, USA.
Bhak RH; Analysis Group, Boston, MA, USA.
Duh MS; Analysis Group, Boston, MA, USA.; Pokaż więcej
Źródło:: Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2156731.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Multiple Myeloma*/drug therapy
Humans ; Bayes Theorem ; Dexamethasone/therapeutic use ; Lenalidomide/therapeutic use ; Network Meta-Analysis ; Systematic Reviews as Topic ; Randomized Controlled Trials as Topic ; Observational Studies as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Predicting anticancer synergistic drug combinations based on multi-task learning.
Autorzy:: Chen D; School of Software Engineering, Tongji University, Shanghai, 201804, China.
Wang X; School of Software Engineering, Tongji University, Shanghai, 201804, China.
Zhu H; School of Software Engineering, Tongji University, Shanghai, 201804, China.
Jiang Y; School of Software Engineering, Tongji University, Shanghai, 201804, China.
Li Y; School of Software Engineering, Tongji University, Shanghai, 201804, China.
Liu Q; Translational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. .
Liu Q; School of Software Engineering, Tongji University, Shanghai, 201804, China. .; Pokaż więcej
Źródło:: BMC bioinformatics [BMC Bioinformatics] 2023 Nov 27; Vol. 24 (1), pp. 448. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:: Journal Article
MeSH Terms:: Computational Biology*/methods
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Neural Networks, Computer ; Drug Combinations

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.
Autorzy:: Wimmer K; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Sachet M; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Ramos C; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Frantal S; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Birnleitner H; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Brostjan C; Department of General Surgery, Division of Vascular Surgery, Medical University of Vienna, 1090, Vienna, Austria.
Exner R; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Filipits M; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Center for Cancer Research, Medical University of Vienna, 1090, Vienna, Austria.
Bago-Horvath Z; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Rudas M; Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Bartsch R; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Department of Medicine 1, Division of Oncology, Medical University of Vienna, 1090, Vienna, Austria.
Gnant M; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
Singer CF; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.; Department of Gynecology, Medical University of Vienna, 1090, Vienna, Austria.
Balic M; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Department of Oncology, Medical University of Graz, Graz, Austria.
Egle D; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Department of Gynecology, Medical University Innsbruck, Innsbruck, Austria.
Oehler R; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. .; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria. .
Fitzal F; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 14; Vol. 42 (1), pp. 300. Date of Electronic Publication: 2023 Nov 14.
Typ publikacji:: Randomized Controlled Trial; Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/pharmacology
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Female ; Humans ; Cyclophosphamide/pharmacology ; Docetaxel/pharmacology ; Epirubicin/pharmacology ; Fluorouracil ; Neoadjuvant Therapy/methods ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji